In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only—we will share insights on the current MASH guidelines. The adoption of the new MASH nomenclature, with the inclusion of cardiometabolic risk factors into its formal definition, will be briefly discussed before examining the different clinical guidelines that are available. We will identify shared recommendations and key points of difference for the screening and management of this complex disease. We will then look to the future to discuss how emerging data may inform future guidelines and help optimize clinical practice. This episode is brought to you by Novo Nordisk Inc.